This study evaluated the long-term efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis who did not meet early treatment response criteria by week 16. Despite 38.1% of patients not reaching the defined response threshold at week 16, many still showed notable improvement, with 58.1% achieving at least a 50% reduction in Eczema Area and Severity Index (EASI). Continued open-label treatment with lebrikizumab through week 52 led to significant clinical benefits: 75.5% reached EASI 75, 44.2% achieved EASI 90, 36.1% reached clear or almost clear skin (IGA 0/1 with ≥2-point improvement), and 66.4% experienced substantial itch relief. The results suggest that extended lebrikizumab treatment may benefit patients who are slower to respond to treatment.
For a link to the original article, click here
Elevate-Derm Alliance Editorial Committee